Jennifer Jackson, Ph.D., has been appointed senior vice president of Regulatory Affairs at Cubist Pharmaceuticals. Dr. Jackson will oversee all regulatory affairs, providing oversight for all U.S. and international regulatory matters, including filings and interactions with regulatory authorities. Dr. Jackson will report to Steve Gilman, Ph.D., Cubist’s executive vice president of R&D and chief scientific officer.
Dr. Jackson joins the company from Biogen Idec Hemophilia, where she was vice president of Regulatory Affairs and Clinical Compliance. Prior to Biogen, Dr. Jackson was vice president of Regulatory Affairs at Vertex Pharmaceuticals and was previously director and vice president of Regulatory Affairs at Biogen Idec.
“I am delighted that Jennifer Jackson has chosen to lead Cubist’s global Regulatory Affairs team,” said Dr. Gilman. “This is a transformational year for the company, and Jennifer’s extensive international experience, collaborative nature, and focus on disciplined execution will help us as we advance our exciting pipeline in the years ahead.”